Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | GUCY1A1 | Q02108 | 9/20 | 0.54 |
| ▸ | GUCY1B1 | Q02153 | 9/20 | 0.54 |
| ▸ | PDE5A | O76074 | 9/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931369 | 1.00 | ADORA3 (0.59) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL30674492 | 1.00 | ADORA3 (0.59) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5775639 | 0.94 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5775654 | 0.94 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL16117653 | 0.89 | ADORA3 (0.60) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL174889 | 0.87 | PDE5A (0.55) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL428374 | 0.87 | PDE5A (0.55) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL29859571 | 0.87 | PDE5A (0.55) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL23161927 | 0.86 | ADORA3 (0.43) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL23161929 | 0.86 | ADORA3 (0.43) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229282-A | Riocigua synthesis process | 安徽美诺华药物化学有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20190284186-A1 | PROCESS FOR PREPARING METHYL{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | ADVERIO PHARMA GMBH (DE) | 2019-09-19 | — | — | US | claimed |
| US-10351562-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | ADVERIO PHARMA GMBH (DE) | 2019-07-16 | — | — | US | claimed |
| US-20180282329-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | ADVERIO PHARMA GMBH (DE) | 2018-10-04 | — | — | US | claimed |
| US-10030014-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | ADVERIO PHARMA GMBH (DE) | 2018-07-24 | — | — | US | claimed |
| WO-2017025981-A1 | PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[L-(2-FHIOROBENZVR)-LH-PYRAZOLO I3,4-BLPVRIDIN-3-VN-5-PYRIMIDINYL(METHVL)CARBAMATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-02-16 | — | — | WO | claimed |
| EP-2604608-B1 | Method for producing methyl- {4,6-diamino-2-[1-(2-fluorobenzyl) -1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-5-yl}-methyl carbamate and its purification for its use as a pharmaceutical agent | ADVERIO PHARMA GMBH (DE) | 2015-10-07 | — | — | EP | claimed |
| US-20140288303-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | claimed |
| US-20130310563-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-21 | — | — | US | claimed |
| US-20110130411-A1 | PROCESS FOR PREPARING METHYL CARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | claimed |
| US-20110130410-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | claimed |
| CN-117229282-A | Riocigua synthesis process | 安徽美诺华药物化学有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-10570130-B2 | Process for preparing methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | ADVERIO PHARMA GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| US-20190284186-A1 | PROCESS FOR PREPARING METHYL{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | ADVERIO PHARMA GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| US-10351562-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | ADVERIO PHARMA GMBH (DE) | 2019-07-16 | — | — | US | disclosed |
| WO-2005046725-A1 | NOVEL COMBINATION CONTAINING A STIMULATOR OF SOLUBLE GUANYLATE CYCLASE AND A LIPID-LOWERING SUBSTANCE | BAYER HEALTHCARE AG (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-20040067937-A1 | Novel sulfonamide-substituted pyrazolopyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-08 | — | — | US | disclosed |
| EP-1339714-A1 | NOVEL SULFONAMIDE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042302-A1 | NOVEL SULFONAMIDE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |
| WO-2001083490-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130410-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | AMD1, TPMT, MMAB | ADORA3 1317/4885KCNH2 748/4885GUCY1A1 1234/4885 |
| US-20180282329-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | TPMT, AMD1, DPYD | ADORA3 1331/4885KCNH2 595/4885GUCY1A1 1723/4885 |
| US-20110130411-A1 | PROCESS FOR PREPARING METHYL CARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | AZI2, TPMT, KDM5B | ADORA3 2401/4885KCNH2 694/4885GUCY1A1 328/4885 |
| US-10351562-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | TPMT, AMD1, DPYD | ADORA3 1267/4885KCNH2 561/4885GUCY1A1 1683/4885 |
| US-10570130-B2 | Process for preparing methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | TPMT, AMD1, DPYD | ADORA3 1267/4885KCNH2 561/4885GUCY1A1 1683/4885 |
| US-20040067937-A1 | Novel sulfonamide-substituted pyrazolopyridine derivatives | GUCY1A2, GUCY1A1, GUCY1B2 | ADORA3 318/4885KCNH2 325/4885GUCY1A1 2/4885 |
| US-10030014-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | TPMT, AMD1, DPYD | ADORA3 1267/4885KCNH2 561/4885GUCY1A1 1683/4885 |
| US-20190284186-A1 | PROCESS FOR PREPARING METHYL{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | TPMT, AMD1, DPYD | ADORA3 1267/4885KCNH2 561/4885GUCY1A1 1683/4885 |
| US-20130310563-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | AMD1, TPMT, MMAB | ADORA3 1317/4885KCNH2 748/4885GUCY1A1 1234/4885 |
| US-20140288303-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | AMD1, TPMT, MMAB | ADORA3 1317/4885KCNH2 748/4885GUCY1A1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.